Evidence map›Paper›PMID 39606809›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Polymeric Multivalent Fc Binding Peptides-Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA-4.

Zongyu Liu, Hongyu Chu, Weidong Zhao, Chenguang Yang, Tongjun Liu, Na Shen, Zhaohui Tang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zongyu LiuDepartment of Colorectal and Anal Surgery, The Second Hospital of Jilin University, Changchun, Jilin, 130000, China.
Hongyu ChuDepartment of Gastrointestinal Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, China.
Weidong ZhaoKey Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China.
Chenguang YangKey Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China.
Tongjun LiuDepartment of Colorectal and Anal Surgery, The Second Hospital of Jilin University, Changchun, Jilin, 130000, China.
Na ShenKey Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China.
Zhaohui TangKey Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China.ORCID 0000-0003-4726-4305

Funding

Jilin Provincial Scientific and Technological Development Program 20230508102RCJilin Provincial Scientific and Technological Development Program 20240305041YYMinistry of Science and Technology of the People's Republic of China 2022YFE0110200National Natural Science Foundation of China 52025035National Natural Science Foundation of China 52073279National Natural Science Foundation of China 52273157Youth Innovation Promotion Association of the Chinese Academy of Sciences 2022224
6 · The paper itself

Abstract

Dual Opdivo plus Yervoy immunotherapy, targeting the immune checkpoints PD1 and CTLA-4, is successful in clinical use. However, it is associated with a high incidence of adverse events, and its therapeutic efficacy needs improving. In this study, polymeric multivalent Fc-binding peptides (PLG-Fc-III-4C) are employed to fabricate a bispecific antibody (PD1/CTLA-4 BsAb) to potentiate dual immunotherapy targeting PD1 and CTLA-4. The PD1/CTLA-4 BsAb is prepared by mixing PLG-Fc-III-4C with aPD1 and aCTLA-4 in an aqueous solution for 3 h using the clinically optimal 3:1 proportion of aPD1 to aCTLA-4. PD1/CTLA-4 BsAb significantly inhibits tumors in MC38 colon cancer-bearing mice more effectively than the combination of aPD1 and aCTLA-4, with tumor suppression rates of 96.8% and 77.3%, respectively. It also induces a higher percentage of CD8

Indexed as

Antibodies, BispecificColonic NeoplasmsCTLA-4 AntigenImmunotherapyPeptidesProgrammed Cell Death 1 ReceptorAnimalsCell Line, TumorFemaleHumansMiceAntibodies, BispecificCTLA-4 AntigenPeptidesProgrammed Cell Death 1 ReceptorCTLA‐4dual immunotherapyFc‐binding peptidePD1polymer

Identifiers

PMID39606809
PMCPMC11744713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.